1. Сhapin J.C, Hajjar K.A. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17-24. DOI: 10.1016/j.blre.2014.09.003
2. Nesheim M, Fredenburgh JC, Larsen GR. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin. J Biol Chem. 1990 Dec 15;265(35):21541-8. DOI: 10.1016/S0021-9258(18)45774-2
3. Hva C.L, Larsen J.B. The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment. Int. J. Mol. Sci. 2023;24(18):14179. DOI: 10.3390/ijms241814179
4. Литвинов Р.И. Молекулярные механизмы и клиническое значение фибринолиза. Казанский медицинский журнал. 2013;4(5):711-718. DOI: 10.17816/KMJ1926
5. Marinho D.S. Perioperative hyperfibrinolysis - physiology and pathophysiology. Braz J Anesthesiol. 2021;71(1):65-75. DOI: 10.1016/j.bjane.2020.12.007
6. Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 2015 Jun;13 Suppl 1:S98-105. DOI: 10.1111/jth.12935
7. Rijken D.C., Lijnen H.R. New insights into the molecular mechanisms of the fibrinolytic system. Journal of Thrombosis and Haemostasis. 2009;7(1):4-13. DOI: 10.1111/j.1538-7836.2008.03220.x
8. Жалялов А.С., Баландина А.Н., Купраш А.Д. и др. Современные представления о системе фибринолиза и методах диагностики ее нарушений. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017;16(1):69-82. DOI: 10.24287/1726-1708-2017-16-1-69-82
9. Hur WS, Mazinani N, Lu XJ, Britton HM, Byrnes JR, Wolberg AS, Kastrup CJ. Coagulation factor XIIIa is inactivated by plasmin. Blood. 2015 Nov 12;126(20):2329-37. DOI: 10.1182/blood-2015-07-650713
10. Longstaff J.C., Kolev K. Basic mechanisms and regulation of fibrinolysis. Journal of Thrombosis and Haemostasis. 2015;13(1):98-105. DOI: 10.1111/jth.12935
11. Boncela J., Przygodzka P., Papiewska-Pajak I. et al. Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli. J Biol Chem. 2011;286(50):43164-43171. DOI: 10.1074/jbc.M111.245647
12. Zahedi R., Davis III A.E. C1 inhibitor: C1 esterase inhibitor, C1 inactivator. The Complement FactsBook. 2000:206-209. DOI: 10.1016/B978-012733360-1/50035-X
13. Тарасова И.В. Система комплемента. Аллергология и иммунология в педиатрии. 2010;2(21):45-46. URL: https://cyberleninka.ru/article/n/sistema-komplementa/pdf.
14. Калинин Р.Е., Климентова Э.А., Сучков И.А. и др. Влияние системы фибринолиза на исходы применения тромболитической терапии при острой сосудистой патологии. Журнал им. Н.В. Склифосовского “Неотложная медицинская помощь”. 2024;13(4):631-640. DOI: 10.23934/2223-9022-2024-13-4-631-640
15. Бокарев И.Н., Мельников А.П., Бурых С.И. Ингибитор фибринолиза, активируемый тромбином, и его клиническое значение. Клиническая медицина. 2023;101(11):521-524. DOI: 10.30629/0023-2149-2023-101-11-521-524
16. Franchini by M., Zaffanello M., Mannucci Р.М. Bleeding Disorders in Primary Fibrinolysis Int. J. Mol. Sci. 2021;22(13): 7027. DOI: 10.3390/ijms22137027
17. Saes J.L., Schols S.E.M., van Heerde W.L. et al. Hemorrhagic disorders of fibrinolysis: a clinical review. Journal of Thrombosis and Haemostasis.2018;16(8):1498-1509. DOI: 10.1111/jth.14160
18. de Jonge J., Groenland T.H., Metselaar H.J. et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg. 2002;94(5):1127-1131. DOI: 10.1097/00000539-200205000-00012
19. Franchini M., Zaffanello M., Mannucci P.M. Bleeding Disorders in Primary Fibrinolysis. Int J Mol Sci. 2021;29;22(13):7027. DOI: 10.3390/ijms22137027
20. Kolev K., Longstaff C. Bleeding related to disturbed fibrinolysis Br J Haematol. 2016;175(1):12-23. DOI: 10.1111/bjh.14255
21. Gao L., Li D., Ding M. Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report. Medicine (Baltimore). 2022;101(29):e29446. DOI: 10.1097/MD.0000000000029446
22. Ващенко В.И., Ващенко Т.Н. Биология и физиология протеина С. Современные представления о механизмах лечебного действия активированного пртеина С. Обзоры по клинической фармакологии и лекарственной терапии. 2009;7(3):24-47. URL: https://cyberleninka.ru/article/n/biologiya-i-fiziologiya-proteina-c-sovremennye-predstavleniya-o-mehanizmah-lechebnogo-deystviya-aktivirovannogo-proteina-s.
23. Ишемический инсульт и транзиторная ишемическая атака. Клинические рекомендации, 2024. Утверждены Минздравом РФ.. URL: https://cr.minzdrav.gov.ru/preview-cr/814_1.
24. Altaf F., Wu S., Kasim V. Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy. Front Mol Biosci. 2021;28(8):680397. DOI: 10.3389/fmolb.2021.68039
25. Shapiro A.D, Menegatti M., Palla R. et al. An international registry of patients with plasminogen deficiency (HISTORY). Haematologica. 2020;105(3):554-561. DOI: 10.3324/haematol.2019.241158
26. Moore H.B. Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States. Semin Thromb Hemost. 2023;49(5):433-443. DOI: 10.1055/s-0042-1758057
27. Gue, Y.X., Ding, W.Y., Lip, G.Y. et al. Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out.2021;3:524. DOI: 10.1007/s42452-021-04517-4
28. Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemost. 2018;16(4):652-662. DOI: 10.1111/jth.13957
29. Zheng Z, Mukhametova L, Boffa MB, Moore EE, Wolberg AS, Urano T, Kim PY. Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. J Thromb Haemost. 2023;21(4):1043-1054. DOI: 10.1016/j.jtha.2023.01.008
30. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102-5. DOI: 10.1182/blood-2004-08-3253
31. Michał Ząbczyk, Robert A S Ariëns, Anetta Undas, Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice, Cardiovascular Research, 2023; 119(1):94-111,. DOI: 10.1093/cvr/cvad017
32. Stanton K, Philippou H, Ariëns RA. Ischaemic Stroke, Thromboembolism and Clot Structure. Neuroscience. 2024;9:550:3-10. DOI: 10.1016/j.neuroscience.2024.02.024
33. Tsantes AG, Parastatidou S, Tsantes EA, Bonova E, Tsante KA, Mantzios PG, Vaiopoulos AG, Tsalas S, Konstantinidi A, Houhoula D, Iacovidou N, Piovani D, Nikolopoulos GK, Sokou R. Sepsis-Induced Coagulopathy: An Update on Pathophysiology, Biomarkers, and Current Guidelines. Life (Basel). 2023;13(2):350. DOI: 10.3390/life13020350
34. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002;132(19-20):241-52. DOI: 10.4414/smw.2002.09856
35. Flores B, Trivedi HD, Robson SC, Bonder A. Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2017;3(3):. DOI: 10.15761/JTS.1000182
36. Saeed Z, Sirolli V, Bonomini M, Gallina S, Renda G. Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients. Int J Mol Sci. 2024;25(16):8705.